| 1475 |
National Cancer Institute |
Html |
en |
Adult Primary Liver Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult primary liver cancer. |
| HCC tumors | 0.58507 |
| Semin Liver Dis | 0.618193 |
| Hepatocellular carcinoma incidence | 0.684284 |
| PDQ cancer information | 0.577886 |
| American Cancer Society | 0.586704 |
| early hepatocellular carcinoma | 0.666995 |
| primary biliary cirrhosis | 0.576504 |
| chronic liver disease | 0.578131 |
| unresectable hepatocellular carcinoma | 0.664574 |
| blood flow | 0.562662 |
| hepatocellular carcinoma | 0.977206 |
| primary liver cancer | 0.589429 |
| Natural history | 0.564684 |
| cancer information summary | 0.576375 |
| risk factors | 0.586296 |
| normal liver parenchyma | 0.570598 |
| liver disease | 0.607293 |
| liver | 0.658374 |
| virus-related hepatocellular carcinoma | 0.677568 |
| western European patients | 0.565566 |
| patients | 0.658086 |
| HCC | 0.686159 |
| advanced-stage HCC | 0.594418 |
| small hepatocellular carcinoma | 0.692383 |
| HCC patients | 0.615983 |
|
| HCC worldwide | 0.602122 |
| single hepatocellular carcinoma | 0.672174 |
| Liver Italian Program | 0.573612 |
| early HCC | 0.59445 |
| entire liver | 0.564284 |
| Liver Diseases | 0.560344 |
| Gastroenterol Hepatol | 0.566445 |
| AASLD hepatocellular carcinoma | 0.670773 |
| untreated hepatocellular carcinoma | 0.669362 |
| study | 0.562576 |
| HCC detection | 0.593776 |
| liver function | 0.561177 |
| PUBMED Abstract | 0.598546 |
| early-stage HCC | 0.580393 |
| class A cirrhosis | 0.563518 |
| arterial blood | 0.606167 |
| liver transplant | 0.559717 |
| cirrhosis | 0.620285 |
| hepatitis b virus | 0.59513 |
| Abstract | 0.629123 |
| cirrhosis type B. | 0.576124 |
| Llovet JM | 0.573361 |
| cm hepatocellular carcinoma | 0.677106 |
| liver resection | 0.566362 |
|
CLICK HERE |
| 1552 |
National Cancer Institute |
Html |
en |
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version |
Childhood ALL is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Here’s what you need to know about the risk factors, signs, tests to diagnose, and treatment of newly diagnosed and recurrent ALL in this expert-reviewed summary. |
| red blood cells | 0.416225 |
| cancer treatment | 0.28631 |
| chemotherapy | 0.431874 |
| treatments | 0.247489 |
| PDQ cancer information | 0.278302 |
| clinical trial search | 0.311111 |
| white blood cells | 0.50903 |
| children | 0.34365 |
| systemic chemotherapy | 0.367092 |
| higher doses | 0.258659 |
| mature blood cells | 0.277223 |
| Natural killer cells | 0.232346 |
| cancer information summary | 0.242631 |
| clinical trial | 0.414978 |
| stem cells | 0.325781 |
| stem cell transplant | 0.490178 |
| Lymphoblastic Leukemia Treatment | 0.242048 |
| blood cells | 0.556083 |
| intrathecal chemotherapy | 0.289545 |
| radiation therapy | 0.442509 |
| General information | 0.218828 |
| child | 0.225345 |
| treatment | 0.73359 |
| immature blood cells | 0.228445 |
| NCI-supported cancer | 0.228604 |
|
| cancer cells | 0.364563 |
| remission induction | 0.378898 |
| anticancer drugs | 0.454791 |
| specific cancer cells | 0.244448 |
| acute lymphocytic leukemia | 0.228943 |
| certain changes | 0.25566 |
| treatment clinical trials | 0.245143 |
| blood stem cells | 0.262182 |
| National Cancer Institute | 0.245665 |
| spinal cord | 0.639894 |
| ) cells. | 0.915202 |
| new treatment | 0.267478 |
| consolidation /intensification | 0.293759 |
| childhood | 0.307766 |
| clinical trials | 0.932686 |
| combination chemotherapy | 0.358378 |
| maintenance phases | 0.246634 |
| brain | 0.275475 |
| bone marrow | 0.619374 |
| Philadelphia chromosome | 0.248781 |
| cancer clinical trials | 0.319159 |
| acute lymphoblastic leukemia | 0.930995 |
| cancer | 0.710977 |
| information | 0.309067 |
|
CLICK HERE |
| 1666 |
National Cancer Institute |
Html |
en |
Testicular Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for testicular cancer. |
| testicular self-exams | 0.545422 |
| ongoing clinical trials | 0.499986 |
| PDQ cancer information | 0.758311 |
| testicular cancer | 0.955987 |
| testicular germ cell | 0.59857 |
| testicular carcinoma | 0.546926 |
| NCI Web site | 0.507088 |
| testicular cancers | 0.553122 |
| clinical trials | 0.669739 |
| early detection | 0.495849 |
| germ cells | 0.505641 |
| cancer information summary | 0.64569 |
| clinical trial | 0.511819 |
| breast cancer prevention | 0.524202 |
| spermatic cord | 0.49407 |
| PDQ summaries | 0.534816 |
| cancer patients | 0.49191 |
| latest published information | 0.509374 |
| NCI’s PDQ | 0.538459 |
| cancer symptoms | 0.51215 |
| NCI PDQ cancer | 0.620022 |
| tests | 0.527688 |
| testicular cancer screening | 0.701295 |
| routine screening test | 0.519043 |
|
| PDQ Screening | 0.553678 |
| testicles | 0.486139 |
| screening tests | 0.48752 |
| Cancer Information Service | 0.545478 |
| common cancer | 0.501504 |
| male sex glands | 0.496865 |
| Prevention Editorial Board | 0.56412 |
| treatment clinical trials | 0.501604 |
| National Cancer Institute | 0.653794 |
| PDQ documents | 0.525451 |
| cancer doctors | 0.485997 |
| long coiled tube | 0.493438 |
| new treatment | 0.506259 |
| health professional version | 0.485461 |
| Cancer screening trials | 0.571582 |
| PDQ database | 0.532773 |
| Cancer Care page | 0.527585 |
| Testicular Cancer Treatment | 0.685082 |
| risk factor | 0.499445 |
| PDQ summary | 0.654344 |
| routine physical exam | 0.576949 |
| cancer information summaries | 0.554625 |
| health professional versions | 0.489301 |
| comprehensive cancer information | 0.555761 |
|
CLICK HERE |
| 1716 |
National Cancer Institute |
Html |
en |
Human Papillomavirus (HPV) Vaccines |
A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer. |
| transmitted HPV types | 0.372301 |
| HPV prophylactic vaccines | 0.352103 |
| anal HPV | 0.291899 |
| HPV transmission | 0.315597 |
| available HPV vaccine | 0.365066 |
| HPV types | 0.787213 |
| Disease Control | 0.208664 |
| HPV vaccination coverage | 0.329587 |
| HPV vaccination program | 0.333099 |
| bivalent HPV vaccination | 0.335395 |
| hpv vaccination | 0.566558 |
| cervical cancer | 0.335142 |
| high-risk HPV infections | 0.38085 |
| HPV surface components | 0.326712 |
| genital HPV infection | 0.36709 |
| available HPV vaccines | 0.389305 |
| persistent HPV | 0.314117 |
| high-risk hpv types | 0.523029 |
| HPV vaccines | 0.696012 |
| human papillomavirus | 0.38319 |
| HPV vaccination series | 0.361602 |
| HPV infections | 0.517426 |
| genital HPV infections | 0.379278 |
| contact. HPV infections | 0.352636 |
| human papillomavirus vaccine | 0.256852 |
|
| hpv infection | 0.466234 |
| current HPV vaccines | 0.379891 |
| women | 0.226009 |
| United States | 0.375279 |
| Updated HPV Vaccination | 0.330423 |
| current HPV infections | 0.328908 |
| therapeutic HPV vaccines | 0.356162 |
| human papillomavirus vaccines | 0.212379 |
| HPV Vaccination Recommendations | 0.367966 |
| Yes. Because HPV | 0.297056 |
| dozen high-risk HPV | 0.362742 |
| HPV | 0.924148 |
| routine HPV vaccination | 0.357555 |
| genital warts | 0.26905 |
| quadrivalent HPV vaccine | 0.329163 |
| additional HPV types | 0.3896 |
| quadrivalent human papillomavirus | 0.21339 |
| HPV vaccine product | 0.372857 |
| additional high-risk HPV | 0.343778 |
| currently approved HPV | 0.315107 |
| high-risk HPV type | 0.392493 |
| Gardasil | 0.309437 |
| vaccine-targeted HPV types | 0.33361 |
| et al | 0.409031 |
|
CLICK HERE |
| 1858 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales. |
| salivary gland carcinoma | 0.756611 |
| salivary neoplasms | 0.424559 |
| estroma linfoide | 0.413137 |
| prognostic factors | 0.41902 |
| gland tumours | 0.43032 |
| Spiro RH | 0.465562 |
| Sin embargo | 0.429856 |
| advanced salivary | 0.421758 |
| Malignant parotid tumors | 0.41189 |
| minor salivary | 0.423431 |
| tumores benignos | 0.597781 |
| Salivary Gland Disease | 0.423228 |
| tumores malignos mixtos | 0.484605 |
| botulinum toxin | 0.428989 |
| Radiat Oncol Biol | 0.471433 |
| glándulas salivales benignos | 0.570833 |
| neck neoplasia following | 0.437258 |
| fuerte predilección | 0.414088 |
| Parotid gland tumours | 0.420714 |
| salivary gland | 0.859636 |
| Head Neck Surg | 0.476609 |
| mucoepidermoid carcinoma | 0.597885 |
| gland malignant neoplasms | 0.445484 |
| tumores benignos mixtos | 0.438326 |
| único sÃntoma | 0.425265 |
|
| parotid gland | 0.431427 |
| lesiones carcinoma | 0.466113 |
| relativa frecuencia | 0.450675 |
| sección carcinoma | 0.486375 |
| carcinoma ex-tumor | 0.470245 |
| unresectable carcinomas | 0.426636 |
| Oral Oncol | 0.420027 |
| major salivary glands | 0.414421 |
| Otolaryngol Head Neck | 0.413034 |
| término carcinoma | 0.475993 |
| carcinoma epidermoide | 0.472012 |
| edad promedio | 0.670934 |
| Salivary Gland Tumours | 0.424182 |
| carcinoma with | 0.481329 |
| adenocarcinoma sai | 0.463524 |
| carcinoma salival basaloide | 0.481935 |
| carcinomas quÃsticos adenoides | 0.459095 |
| Botulinum toxin treatment | 0.413697 |
| with parotid carcinoma | 0.483397 |
| Oncol Biol Phys | 0.47266 |
| linfadenoma sebáceo | 0.417003 |
| elemento carcinoma | 0.475416 |
| carcinoma mucoepidermoide | 0.988653 |
| neoplasias benignas | 0.45166 |
|
CLICK HERE |
| 4300 |
National Cancer Institute |
Html |
en |
Cancer Moonshot℠ Blue Ribbon Panel |
The Blue Ribbon Panel Report outlines 10 recommendations to accelerate progress against cancer. The panel was established to ensure that the Cancer Moonshot's approaches are grounded in the best science. |
| BRP | 0.544911 |
| National Cancer Advisory | 0.917882 |
| pediatric cancer | 0.537601 |
| relevant scientific sectors | 0.512578 |
| Reduce cancer risk | 0.54942 |
| dynamic 3D maps | 0.479491 |
| early detection | 0.494934 |
| therapeutic targets | 0.493364 |
| presidentially appointed National | 0.528792 |
| new preclinical models | 0.493659 |
| national cancer data | 0.584851 |
| previously effective treatments | 0.485016 |
| early detection strategies | 0.482919 |
| new therapeutic targets | 0.480719 |
| cancer resistance | 0.471789 |
| E. Intensify research | 0.49241 |
| translational science network | 0.495254 |
| cancer technologies | 0.513048 |
| public idea submission | 0.473834 |
| broader cancer community | 0.579774 |
| transformative research recommendations | 0.554836 |
| cancer immunotherapy network | 0.593107 |
| Ribbon Panel report | 0.661804 |
| tumor evolution | 0.579883 |
|
| cancer health disparities | 0.557334 |
| final recommendations | 0.465114 |
| Cancer Immunology | 0.464811 |
| human tumor evolution | 0.504864 |
| specific recommendations | 0.466439 |
| cancer prevention | 0.548373 |
| C. Develop ways | 0.499508 |
| tumor profile data | 0.530939 |
| cancer cells | 0.472187 |
| group members | 0.429792 |
| Minimize cancer treatment | 0.561924 |
| direct patient involvement | 0.494413 |
| joint recommendations | 0.465939 |
| 3D cancer atlas | 0.546232 |
| multiple groups | 0.44011 |
| Cancer Moonshot Task | 0.60025 |
| Blue Ribbon Panel | 0.890429 |
| groups | 0.493987 |
| BRP members | 0.537843 |
| major topic areas | 0.508582 |
| Cancer Advisory Board | 0.925259 |
| efficient data analysis | 0.49446 |
| Develop new cancer | 0.562862 |
| future patient outcomes | 0.484191 |
|
CLICK HERE |
| 15882 |
National Cancer Institute |
Html |
es |
Cardo mariano (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del cardo mariano como tratamiento para personas con cáncer. |
| Silybum marianum | 0.735385 |
| Agarwal R | 0.945743 |
| cell lines | 0.375003 |
| cell growth | 0.494513 |
| prostate carcinoma du145 | 0.373715 |
| DNA synthesis | 0.442196 |
| carcinoma cell | 0.46955 |
| silybum marianum l | 0.361146 |
| Inhibitory effect | 0.390679 |
| Agarwal C | 0.386743 |
| receptor modulator activity | 0.356592 |
| Mol Carcinog | 0.378538 |
| Cancer Res | 0.59348 |
| carcinoma cell growth | 0.407562 |
| prostate carcinoma cells | 0.4865 |
| Singh RP | 0.367955 |
| flavonoid antioxidant | 0.678831 |
| active constituent | 0.382485 |
| Antiproliferative effect | 0.363827 |
| lipid peroxidation | 0.585387 |
| Biochem Pharmacol | 0.461277 |
| chemopreventive effects | 0.369648 |
| cardo lechero | 0.365629 |
| patients with | 0.374862 |
| cell growth inhibition | 0.393232 |
|
| Sonnenbichler J | 0.428511 |
| prostate carcinoma | 0.590474 |
| Campos R | 0.414926 |
| Pharmacol Res | 0.429959 |
| protective effects | 0.379153 |
| Biophys Res Commun | 0.50103 |
| prostate-specific antigen with | 0.369145 |
| carcinoma du145 cells | 0.397873 |
| Biochem Biophys Res | 0.508991 |
| Silymarin effects | 0.38621 |
| Biomed Res Int | 0.385769 |
| Clin Biol Res | 0.375557 |
| insulin-like growth factor-binding | 0.358425 |
| stimulatory effects | 0.357205 |
| Zhao J | 0.53049 |
| Guerra R | 0.490633 |
| with cell growth | 0.41107 |
| comparison with | 0.378495 |
| silibinin inhibits | 0.378656 |
| Planta Med | 0.529049 |
| protects against | 0.371646 |
| Mutat Res | 0.369799 |
| from silybum marianum | 0.396284 |
| Res Commun | 0.505421 |
|
CLICK HERE |
| 16049 |
National Cancer Institute |
Html |
en |
Managing Costs and Medical Information |
People with cancer may face major financial challenges and need help dealing with the high costs of care. Cancer treatment can be very expensive, even when you have insurance. Learn ways to manage medical information, paperwork, bills, and other records. |
| cancer treatment | 0.452926 |
| file folder | 0.451204 |
| emergency room | 0.448618 |
| medical bills | 0.53618 |
| state specific information | 0.467913 |
| insurance coverage | 0.460494 |
| health care team | 0.51276 |
| American Cancer Society | 0.460319 |
| payment options | 0.46621 |
| non-medical phone calls | 0.432178 |
| social worker | 0.59281 |
| clinical trials | 0.467219 |
| health care providers | 0.479775 |
| State Health Insurance | 0.507522 |
| cancer care | 0.486022 |
| research costs | 0.450096 |
| Track daily events | 0.441284 |
| Insurance Assistance Service | 0.484543 |
| health care costs | 0.531061 |
| patient care costs | 0.553498 |
| travel costs | 0.463012 |
| government health insurance | 0.504906 |
| treatment | 0.485685 |
| electronic medical record | 0.447232 |
| health care bills | 0.536309 |
|
| insurance company pay | 0.509196 |
| help finding referrals | 0.489042 |
| Cancer Information Service | 0.588627 |
| financial issues | 0.432149 |
| Health Insurance Assistance | 0.617568 |
| special email account | 0.433974 |
| sample chart | 0.453844 |
| discount drug programs | 0.446076 |
| separate folder | 0.500544 |
| extra costs | 0.480459 |
| bills | 0.574419 |
| hospital | 0.455427 |
| health care | 0.679621 |
| key medical information | 0.460671 |
| insurance company | 0.914855 |
| costs | 0.714673 |
| NCI Cancer Information | 0.458766 |
| important medical information | 0.475214 |
| human resources department | 0.455264 |
| medicine | 0.454681 |
| health care coverage | 0.489272 |
| insurance companies | 0.472181 |
| doctor | 0.602384 |
| mobile device | 0.452113 |
|
CLICK HERE |
| 17193 |
National Cancer Institute |
Html |
en |
U.S. - China Program for Biomedical Research Cooperation |
U.S. - China Program for Biomedical Research Cooperation Preliminary Program Review. |
| Office | 0.440565 |
| OAR | 0.472714 |
| Allergy | 0.446266 |
| scientific accomplishments | 0.62865 |
| projects | 0.51324 |
| Additional outcomes | 0.632018 |
| National Natural Science | 0.9169 |
| Mental Health | 0.663295 |
| Chinese scientists | 0.664312 |
| translational biomedical research. | 0.976759 |
| National Cancer Institute | 0.919012 |
| Foundation | 0.442112 |
| preliminary evaluation | 0.675445 |
| US-China | 0.436834 |
| results | 0.435543 |
| National Institute | 0.932171 |
| National Institutes | 0.697264 |
| common successes | 0.636736 |
| Administrative Supplements | 0.654736 |
| Stroke | 0.440417 |
| Collaborative Biomedical Research | 0.935063 |
|
| Global Health | 0.637782 |
| NSFC | 0.441999 |
| future collaborative programs | 0.854353 |
| impacts | 0.442029 |
| countries | 0.439905 |
| NIAID | 0.482086 |
| NIH | 0.458074 |
| international collaboration | 0.640713 |
| joint initiative | 0.663479 |
| Neurological Disorders | 0.660677 |
| NIMH | 0.468305 |
| Researchers | 0.441544 |
| U.S.-China Program | 0.677605 |
| report | 0.435896 |
| Infectious Diseases | 0.665033 |
| scientifically meritorious investigations | 0.921915 |
| Biomedical Research Cooperation | 0.865108 |
| Preliminary Program Review | 0.859879 |
| AIDS Research | 0.660227 |
| R01 mechanisms | 0.711872 |
|
CLICK HERE |
| 17294 |
National Cancer Institute |
Html |
es |
Anemia |
Información y consejos para controlar la anemia, un efecto secundario del tratamiento del cáncer.
|
| suficientes glóbulos | 0.941582 |
|
|
CLICK HERE |